Acute Toxicities with BCMA-directed T-cell therapies

Tweetorial #4


This activity is jointly provided by Global Education Group and Bonum CE.

Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Pfizer.

Program Overview

Determining appropriate treatment for multiple myeloma (MM) is complex due to the heterogeneity of the patient population, the occurrence of multiple disease relapses and the availability of multiple treatment options. B-cell maturation antigen BCMA is an attractive therapeutic target for RRMM because overexpression and activation of BCMA are associated with progression of MM. Knowledge regarding differentiating BCMA-targeted agents, determining appropriate patients for BCMA-targeted therapies, as well as potential for sequencing these agents are important for health care providers (HCPs) caring for patients with RRMM. Understanding the underlying mechanisms of response and toxicity of BCMA-directed therapies in patients with MM is critical to appropriate use of these therapies.

This Twitter-based Tweetorial will explore the safety of BCMA-directed therapies for MM, as well as best practices to manage acute toxicities associated with these agents.

Faculty

Joseph Mikhael, MD, MEd, FRCPC (program co-chair)
Professor Applied Cancer Research and Drug Discovery
Translational Genomics Research Institute
Phoenix, AZ

Chng Wee Joo, PhD (guest faculty)
Professor Department of Hematology & Oncology
Yong Loo Lin School of Medicine
National University of Singapore
National University Cancer Institute, Singapore
National University Health System
Singapore, Singapore

Target Audience

This program is intended for Hematologists, Medical Oncologists, hematology and oncology fellows, and specialty advanced practice providers involved in the treatment of patients with multiple myeloma. Nurses, pharmacists, researchers, and other health care practitioners (HCPs) involved in the treatment of patients with RRMM may be interested in this program.

Learning Objectives

After completing this activity series, the participant should be better able to translate strategies to monitor and minimize the negative impact of treatment-related toxicities for BCMA-directed therapies in RRMM

Disclosure of Relevant Financial Relationships

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

 

  • Joseph Mikhael, MD, Med, FRCPC
    Consulting: Amgen, Bristol Myers Squibb, Janssen, Sanofi

    Chng Wee Joo, PhD
    Honoraria: AbbVie, Antengene, Amgen, Bristol Myers Squibb, J&J, Sanofi

  • The planners and managers at Global Education Group have no relevant financial relationships to disclose.

    Bonum CE staff and others involved with the planning, development, and review of the content for this activity have no relevant financial relationships to disclose.

Certification

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Bonum Continuing Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit & Fee Information

In order to receive credit for this activity, the participant must read the front matter, achieve a passing score of 100% on the post-test, complete the evaluation and application for credit form.

There is no fee to participate in this activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group, collaborators, and faculty on this program do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

System Requirements

All Bonum CE digital activities require the following hardware/software to view and participate:

  • Internet connection (via PC or Mac desktop or laptop computer, tablet, mobile device, etc.)

  • PowerPoint and/or a PDF viewer may be required on some activities

We recommend a minimum of:

  • 128MB RAM

  • Processor speed of 500MHz or higher

  • 800x600 color monitor

  • Video or graphics card

  • Sound card and speakers

To actively participate in Bonum’s social media (SoMe)-based CME programs, learners will need to have an established account in good standing on that hosting SoMe site. Learners will need to be logged-in to the SoMe hosting platform.

Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Release date: October 20, 2023
Expiration date: October 19, 2024
Estimated time to complete activity: 15 minutes